Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Brève: Premier traitement du MERS en essai clinique</title></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmc">7140275</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140275</idno><idno type="RBID">PMC:7140275</idno><idno type="doi">10.1016/S1773-035X(16)30316-1</idno><idno type="pmid">NONE</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000649</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000649</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Brève: Premier traitement du MERS en essai clinique</title></analytic><series><title level="j">Revue Francophone Des Laboratoires</title><idno type="ISSN">1773-035X</idno><idno type="eISSN">1773-0368</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="brief-report" xml:lang="fr"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Francoph Lab</journal-id><journal-id journal-id-type="iso-abbrev">Rev Francoph Lab</journal-id><journal-title-group><journal-title>Revue Francophone Des Laboratoires</journal-title></journal-title-group><issn pub-type="ppub">1773-035X</issn><issn pub-type="epub">1773-0368</issn><publisher><publisher-name>Elsevier Masson SAS.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">7140275</article-id><article-id pub-id-type="publisher-id">S1773-035X(16)30316-1</article-id><article-id pub-id-type="doi">10.1016/S1773-035X(16)30316-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Brève: Premier traitement du MERS en essai clinique</article-title></title-group><pub-date pub-type="pmc-release"><day>9</day><month>11</month><year>2016</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>11</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>9</day><month>11</month><year>2016</year></pub-date><volume>2016</volume><issue>486</issue><fpage>18</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright © 2016 Elsevier Masson SAS. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Elsevier Masson SAS</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><p id="par0005"><fig id="fig0005"><caption><p>© Onidji/Fotolia.com</p></caption><graphic xlink:href="gr1"></graphic></fig></p><p id="par1005">Aux USA, les NIH évaluent un traitement-candidat du MERS-CoV (<italic>Middle East Respiratory Syndrome-Coronavirus</italic>), ou syndrome respiratoire du Moyen-Orient à Coronavirus, proposé par la biopharma SAB Biotherapeutics. Cet essai de phase 1 est conduit par les NIH pour évaluer le dosage et la sécurité de ce traitement, à base d’anticorps humains, ou SAB-301. Le MERS-CoV est une maladie respiratoire récemment découverte, il n’existe encore ni vaccin ni traitement. SAB Therapeutics produit le SAB-301 sur sa plateforme DiversitAb<sup>®</sup>, à partir de bétail génétiquement modifié (Tc Bovine<sup>®</sup>) pour produire de grandes quantités d’anticorps polyclonaux humains (immunoglobuline G) en réponse à l’administration de l’antigène viral du MERS. Les bovins produisent rapidement d’importantes quantités d’anticorps humains, recueillis dans le plasma et purifiés Selon SAB, la plateforme DiversitAb<sup>®</sup> est la première à partir de laquelle des anticorps entièrement humains ont été produits sur de grands animaux. Les premiers résultats devraient être publiés début 2017</p></body><back><ref-list id="fur0005"><title>Source</title><ref id="bib1010"><mixed-citation publication-type="other" id="oref0005"><ext-link ext-link-type="uri" xlink:href="http://www.sabbiotherapeutics.com/" id="intr0005">www.sabbiotherapeutics.com</ext-link></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000649 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000649 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |